Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLARITY-Gastric 02: Sonesitatug vedotin + capecitabine ± rilvegostomig in first-line CLDN18.2-positive gastric/GEJ/esophageal adenocarcinoma
jRCT2031250781Recruiting
- Sponsor
- AstraZeneca
- Start
- Mar 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
Randomised trial of sonesitatug vedotin in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and esophageal adenocarcinoma (EAC) (4 cohorts), sponsored by AstraZeneca. Primary endpoints: Progression Free Survival (PFS) and Overall Survival (OS). Started Mar 2026; status: recruiting.
02
Drugs
sonesitatug vedotin
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on jRCT2031250781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250781.